The combinations of dabrafenib + trametinib, vemurafenib + cobimetinib, and encorafenib + binimetinib have demonstrated efficacy against melanomas with mutations in both the NRAS and BRAF genes, and are shown to improve therapy response and overall PFS (Flaherty et al., 2012; Ascierto et al., 2013; Larkin et al., 2014; Long et al., 2015; Robert et al., 2015). The gene discussed is BRAF; the disease is melanoma.